Loading...

Financial Summary


KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc. (KALV)

Healthcare
Buy
B+
Market Info
Financial Info
Financial Modelling
Symbol KALV
Price 14.82$
Beta 2.44
Volume Avrg. 0.03M
Market Cap 0.22B
Shares (2019) 15,080.86K
Last Div 0
Dividend Yield -
DCF Unlevered -34,297,064.35 Strong Sell
DCF Levered -26,082,588.80 Strong Sell
ROE -21.52% Sell
ROA -20.84% Sell
Operating Margin -184.91% Strong Sell
Debt / Equity 0.06% Neutral
P/E - Neutral
P/B 4.09 Strong Buy

Income Statement

Download KALV income statement Download KALV income statement
Year 2012 2013 2014 2015 2016 2017 2018 2019
Earnings Per Share Basic -71.96-187.88-305.34-18.20-26.17-4.47-1.53-1.38
Net Profit Margin -1.33-13.68-460.66-856.76-5.36-12.37-1.88-1.29
Earnings Per Share Diluted -71.96-187.88-305.34-18.20-26.17-4.47-1.53-1.38
Revenue 1.540.410.030.032.131.508.3916.13
Weighted Average Shares Outstanding 0.030.030.041.360.594.6510.3215.08
Gross Profit 0.410.03-6.480.032.131.508.3916.13
Weighted Average Shares Outstanding (Diluted) 0.030.030.041.360.594.6510.3215.08
Sales, General and Administrative Expense 1.411.403.414.872.6511.188.8610.93
Dividend per Share --------
Operating Income -5.22-11.68-8.09-21.04-15.18-22.34-18.70-29.82
Gross Margin 1.001.001.001.001.001.001.001.00
Earnings before Tax -2.05-5.68-13.36-24.85-11.44-18.60-15.80-20.69
EBITDA Margin -1.14-12.64-421.48-811.21-5.35-12.34-1.86-1.26
Net Income -2.05-5.68-13.36-24.85-11.44-18.60-15.80-20.82
EBIT Margin -1.17-12.71-423.34-815.79-5.36-12.37-1.88-1.28
Net Income - Discounted ops --------
Profit Margin -1.41-13.68-460.65-856.76-5.36-12.37-1.88-1.29
Preferred Dividends 0.11-------
Free Cash Flow margin -0.00-0.00-0.00-0.00-0.00-0.000.00-0.00
R&D Expenses 1.964.238.2916.2014.6612.6718.2435.02
Interest Expense 0.411.08-1.19----
Earnings Before Tax Margin -1.33-13.68-460.66-856.76-5.36-12.37-1.88-1.28
Consolidated Income -2.05-5.68-13.36-24.85-11.44-18.60-15.80-20.82
EBIT -5.27-12.28-8.09-23.66-11.44-18.60-15.80-20.69
EBITDA -1.76-5.25-12.22-23.52-11.40-18.56-15.63-20.31
Income Tax Expense -------0.12
Operating Expenses 5.6311.719.8921.0717.3123.8427.1045.95
Cost of Revenue --------
Net Income Com -2.16-5.68-13.36-24.85-11.44-18.60-15.80-20.82
Net Income - Non-Controlling int --------

Balance Sheet Statement

Download KALV income statement Download KALV income statement
Year 2013 2014 2016 2017 2018 2019
Total current liabilities 7.091.843.253.0223.2218.05
Other Liabilities 1.631.152.111.8621.5615.14
Long-term debt 2.13---0.06-
Cash and cash equivalents 3.952.5321.7630.9551.0532.01
Total debt 3.066.57--0.280.05
Cash and short-term investments 3.952.5321.7630.9551.05100.81
Deferred revenue 0.140.11--29.3412.89
Inventories ------
Tax Liabilities ------
Goodwill and Intangible Assets ------
Deposit Liabilities ------
Tax assets --1.882.256.8311.31
Total non-current liabilities 0.314.1858.61-10.923.34
Total current assets 0.202.060.070.152.012.59
Total liabilities 11.271.8461.863.0234.1421.39
Payables 1.020.691.141.151.432.86
Other comprehensive income ---0.07-2.64-1.11-1.93
Short-term investments -----68.81
Retained earnings (deficit) -47.77-25.82-37.25-55.85-71.66-92.48
Property, Plant & Equipment Net 0.180.100.070.101.842.41
Total non-current assets 0.314.1858.61-10.923.34
Other Assets 0.080.642.552.958.3214.73
Net Debt -6.772.62-21.76-30.95-50.78-100.76
Investments -----68.81
Total shareholders equity -44.18-23.55-37.1131.3327.2596.74
Total assets 6.643.8924.7534.3461.39118.13
Long-term investments ------
Receivables -1.050.360.30--
Short-term debt 4.43---0.220.05

Cash Flow Statement

Download KALV income statement Download KALV income statement
Year 2012 2013 2014 2015 2016 2017 2018 2019
Insurance (repayment) of debt --------
Net Cash/Marketcap 0.000.000.000.000.000.000.000.00
Insurance (buybacks) of shares --------
Depreciation & Amortization 0.040.030.050.130.030.040.180.38
Dividend payments --------
Operating Cash Flow -4.86-11.25-6.37-20.86-13.16-23.7210.56-36.37
Acquisitions and disposals -----34.14--
Free Cash Flow -1.93-4.88-11.41-22.24-13.17-23.809.13-37.45
Net cash flow / Change in cash 3.641.54-5.8849.8319.249.1920.11-19.05
Effect of forex changes on cash -----0.60-1.161.99-1.21
Financing Cash Flow 6.425.538.6672.0633.000.008.9987.94
Investment purchases and sales --------68.34
Capital Expenditure -0.02-0.16-0.13-1.37-0.01-0.07-1.43-1.08
Stock-based compensation 0.050.240.380.790.120.391.062.97
Investing Cash Flow --------

Retained Earning Schedule

Year 2013 2014 2016 2017 2018 2019
Retained Earnings (Previous Year) --48--37-56-72
Net Income -6-13-11-19-16-21
Stock Dividends -4235-26---
Divident Paid ------
Retained Earnings -48-26-37-56-72-92

PPE Schedule

Year 2013 2014 2016 2017 2018 2019
Year 201320142016201720182019
Gross PPE -0-002
Annual Depreciation 000032
Capital Expenditure -0-0-0-0-1-1
Net PPE 000022

Intangible and Goodwill Schedule

Year 2013 2014 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) ------
New Purchases ------68
Intangible and Goodwill ------
KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc. (KALV)

14.82
-0.11 (-0.74%)

About


Thomas Andrew Crockett
Healthcare
Biotechnology
NASDAQ Global Market

KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.